WuXi Biologics Completes Multiple Global Regulatory Inspections
WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility Read More

WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility Read More

WuXi Biologics Receives GMP Conformity Assessment from the Singapore Health Sciences Authority (HSA) Read More
Jan 10-13, 2022
40th J.P. Morgan Healthcare Conference

Jan 17-19, 2022
Our Regulatory Affairs team provides a quarterly summary of updates organized by agency and by topic. These updates support your efforts to stay current in our ever-changing regulatory environment.
For more information on our Quality track record, please click this infographic.
WuXi Biologics Congratulates Amicus on U.S. FDA’s Acceptance of its Filing for AT-GAA for the Treatment of Pompe Disease
To read more about WuXi Biologics visit our Newsletter Archive
Follow Us!